The “Mexican method” to autograft autoimmune patients employs cyclophosphamide and rituximab as conditioning regimens. The method is started on an outpatient basis in all cases and completed on an outpatient basis in around 90% of individuals. Less than 10% of patients need to be admitted into the hospital. The method is registered in